Luminita Pricop

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 827 citations

Inflammation, Rheumatology, Autoimmune Disease +8

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Philip J. Mease, Iain B. McInnes, Bruce Kirkham et al. · New England Journal of Medicine · 2015 · 723 citations · Full text

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Philip J. Mease, Désirée van der Heijde, Robert Landewé et al. · Annals of the Rheumatic Diseases · 2018 · 284 citations · Full text

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Iain B. McInnes, Frank Behrens, Philip J. Mease et al. · The Lancet · 2020 · 271 citations · Full text

Rheumatology, Autoimmune Disease, Medicine +10

Differential Modulation of Stimulatory and Inhibitory Fcγ Receptors on Human Monocytes by Th1 and Th2 Cytokines

Luminita Pricop, Patricia Redecha, Jean‐Luc Teillaud et al. · The Journal of Immunology · 2001 · 227 citations · Full text